文献速递造血干细胞移植与细胞治疗淋巴瘤

移植后环磷酰胺对比基于他克莫司的移植物抗宿主病预防:复发与慢性移植物抗宿主病发生率更低

Posttransplant cyclophosphamide vs tacrolimus-based GVHD prophylaxis: lower incidence of relapse and chronic GVHD.
PubMed 文献 · Blood Adv · 2023-01-01

本研究比较移植后环磷酰胺(PTCY)方案与基于他克莫司的常规方案在HLA相合同胞无关供者外周血干细胞移植中的移植物抗宿主病预防效果。107例成人接受PTCY方案,463例接受他克莫司方案。PTCY组2年中度至重度慢性移植物抗宿主病为12%对36%(P<.0001),复发为25%对34%(P=.027),无进展生存为64%对54%(P=.02)。

要点

  • PTCY组2年中度至重度慢性移植物抗宿主病12% vs 他克莫司组36%(P<.0001)。
  • PTCY组2年复发25% vs 他克莫司组34%(P=.027),主要见于减低强度预处理患者。
  • PTCY组2年无进展生存64% vs 他克莫司组54%(P=.02)。

核心结论

  • 研究结果提示,在接受HLA相合同胞无关供者外周血干细胞移植的患者中,PTCY预防方案与较低的复发率和慢性移植物抗宿主病发生率相关。

研究设计与样本

  • 本研究为单中心机构经验性研究,比较PTCY方案与他克莫司方案用于移植物抗宿主病预防。
  • PTCY组107例成人,他克莫司组463例成人,均接受外周血干细胞移植。
  • 两组基线特征均衡,但PTCY组更多患者接受了7/8相合的外周血干细胞移植。

主要发现

  • 急性移植物抗宿主病发生率两组无差异。
  • 2年中度至重度慢性移植物抗宿主病:PTCY组12% vs 他克莫司组36%(P<.0001)。
  • 2年复发率:PTCY组25% vs 他克莫司组34%(P=.027),主要见于接受减低强度预处理的患者。
  • 2年无进展生存:PTCY组64% vs 他克莫司组54%(P=.02)。
  • 多因素分析:无进展生存的风险比(HR)为0.59(P=.015),中度至重度慢性移植物抗宿主病的亚分布风险比为0.27(P<.0001),复发的亚分布风险比为0.59(P=.015)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The ability of posttransplant cyclophosphamide (PTCY) to facilitate haploidentical transplantation has spurred interest in whether PTCY can improve clinical outcomes in patients with HLA-matched unrelated donors undergoing peripheral blood stem cell transplantation (PBSCT). We investigated our institutional experience using PTCY-based graft-versus-host disease (GVHD) prophylaxis compared with conventional tacrolimus-based regimens. We compared overall survival, progression-free survival (PFS), relapse, nonrelapse mortality, and acute and chronic GVHD in 107 adult patients receiving a PTCY-based regimen vs 463 patients receiving tacrolimus-based regimens for GVHD prophylaxis. The 2 cohorts were well balanced for baseline characteristics except that more patients in the PTCY cohort having received 7-of-8-matched PBSCT. There was no difference in acute GVHD. All-grade chronic GVHD and moderate-to-severe chronic GVHD were substantially reduced in patients receiving PTCY compared with in those receiving tacrolimus-based regimens (2-year moderate-to-severe chronic GVHD: 12% vs 36%; P < .0001). Recipients of PTCY-based regimens also had a lower incidence of relapse compared with recipients of tacrolimus-based regimens (25% vs 34% at 2-years; P = .027), primarily in patients who received reduced intensity conditioning. This led to improved PFS in the PTCY cohort (64% vs 54% at 2 years; P = .02). In multivariable analysis, the hazard ratio was 0.59 (P = .015) for PFS and the subdistribution hazard ratio was 0.27 (P < .0001) for moderate-to-severe chronic GVHD and 0.59 (P = .015) for relapse. Our results suggest that PTCY prophylaxis is associated with lower rates of relapse and chronic GVHD in patients who receive HLA-matched unrelated donor PBSCT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Maurer K, Ho VT, Inyang E, et al. Posttransplant cyclophosphamide vs tacrolimus-based GVHD prophylaxis: lower incidence of relapse and chronic GVHD. Blood Adv. 2023. PMID: 37156098. doi:10.1182/bloodadvances.2023009791

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。